In Singapore, 10.5 percent of adults aged between 18 and 69 years are affected by asthma. Suboptimal asthma control imposes a significant burden on healthcare systems and society. Short-acting betaagonists (SABA) monotherapy had been the standard asthma treatment for many years in patients with mild asthma symptoms. However, according to current guidelines and new recommendations, SABAs are no longer recommended as the preferred reliever for patients when they are symptomatic and should not be used as monotherapy due to significant safety concerns and poor outcomes. In this article, we will review the current guideline recommendations and accompanying evidence for the treatment and management of asthma in clinical practice.